Randi Bragg, NP
Family · Marion, INNPI 1700420031
Payments from drug & device makers
Across 249 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$377
- Otsuka America Pharmaceutical, Inc.$340
- Supernus Pharmaceuticals, Inc.$284
- Lilly USA, LLC$257
- Corium, LLC$224
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,70698%
- Education$842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,153 |
| GSK | 5 | $377 |
| Otsuka America Pharmaceutical, Inc. | 14 | $340 |
| Supernus Pharmaceuticals, Inc. | 14 | $284 |
| Lilly USA, LLC | 21 | $257 |
| Corium, LLC | 20 | $224 |
| Axsome Therapeutics, Inc. | 10 | $209 |
| Corcept Therapeutics | 5 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $183 |
| AstraZeneca | 10 | $174 |
| Pfizer | 10 | $169 |
| Vanda Pharmaceuticals Inc. | 12 | $157 |
| Bayer | 3 | $151 |
| Gilead | 8 | $151 |
| Exact Sciences | 6 | $145 |
| Novo Nordisk | 7 | $116 |
| Avanir Pharmaceuticals, Inc. | 3 | $70 |
| Organon | 4 | $60 |
| Amgen | 3 | $59 |
| Alkermes, Inc. | 3 | $51 |
| Biogen | 2 | $50 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Lundbeck LLC | 2 | $34 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,790 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 51 | $73,030 |
| TrulicityDulaglutide | 52 | $58,113 |
| Dupixent PenDupilumab | 14 | $53,212 |
| OzempicSemaglutide | 39 | $44,159 |
| VraylarCariprazine Hcl | 26 | $36,360 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $28,679 |
| JanuviaSitagliptin Phosphate | 36 | $26,240 |
| Nurtec OdtRimegepant Sulfate | 17 | $19,839 |
| JardianceEmpagliflozin | 18 | $17,941 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $10,963 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $9,723 |
| TrintellixVortioxetine Hydrobromide | 11 | $5,232 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $2,926 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,457 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $2,381 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $257 | $131,143103 claims |
| Novo NordiskOzempic | $116 | $44,15939 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta | $377 | $42,10071 claims |
| AbbVieVraylar | $1,153 | $36,36026 claims |
| MerckJanuvia | $14 | $26,24036 claims |
| PfizerNurtec Odt | $169 | $19,83917 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $183 | $5,23211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Marion
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.